Maryland BioIndustry News

GenVec names Cynthia Collins new CEO

Mon, 21 May 2012 16:42:00 EDT

Gaithersburg-based vaccine developer GenVec Inc., whose chief executive Paul Fischer announced plans to retire in December, has named industry veteran Cynthia Collins as president and CEO.

Emergent BioSolutions approves $35 million stock buyback

Mon, 21 May 2012 16:36:00 EDT

Rockville-based Emergent BioSolutions Inc. has launched a share repurchase program for up to $35 million of the company’s common stock.

GlycoMimetics, partners developing AIDS vaccine

Mon, 21 May 2012 15:30:00 EDT

GlycoMimetics will work with the nonprofit International AIDS Vaccine Initiative and Glycosensors and Diagnostics LLC on the vaccine that will use compounds that mimic carbohydrates, called glycomimetics.

Emergent gets FDA approval for modified vaccine dosing

Mon, 21 May 2012 13:43:00 EDT

Rockville-based Emergent BioSolutions Inc. which makes the only vaccine licensed by the Food and Drug Administration to protect against anthrax infection, has received FDA approval for a new, shorter-dosing schedule.

Human Genome Sciences enters talks with potential suitors

Mon, 21 May 2012 13:10:00 EDT

Human Genome Sciences Inc. entered into confidentiality agreements with “certain parties” and is providing an opportunity to engage in due diligence reviews, the Rockville-based company said Thursday.

World's First Approved Stem Cell Drug; Osiris Receives Marketing Clearance from Health Canada for Prochymal

Mon, 21 May 2012 12:57:00 EDT

Osiris Therapeutics Inc. announced today it has received market authorization from Health Canada to market its stem cell therapy Prochymal® (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children.

Sucampo Pharmaceuticals cuts losses

Fri, 11 May 2012 10:14:00 EDT

Bethesda-based Sucampo Pharmaceuticals Inc., with one drug to treat bowel dysfunction on the market and another heading toward a regulatory review, cut losses last quarter on lower research and development costs.

EntreMed keeps its listing

Fri, 11 May 2012 09:44:00 EDT

Rockville-based EntreMed Inc. which was warned in November it was at risk of losing its Nasdaq stock market listing, will now keep it.

GenVec revenue falls, loss widens

Fri, 11 May 2012 09:40:00 EDT

Gaithersburg-based GenVec Inc. posted a wider loss in its latest quarter as cost reductions failed to make up for a drop in revenue.

Biowatch: Supernus debuts on the Nasdaq, awaits ruling on epilepsy drugs

Tue, 08 May 2012 14:26:00 EDT

Supernus Pharmaceuticals, the Rockville biotech that’s developing drugs to treat epilepsy, depression and attention deficit hyperactivity disorder, got off to a solid start in its first week of trading as a public company.

BioMed adds two Rockville buildings in $26.2M deal

Tue, 08 May 2012 14:13:00 EDT

BioMed Realty Trust of San Diego has announced plans to buy two more Rockville laboratory and office buildings for $26.2 million.

Supernus moves from IPO to FDA

Tue, 08 May 2012 11:10:00 EDT

Supernus Pharmaceuticals Inc. capped off its first week on the Nasdaq up nearly $1 from its initial public offering price. With its IPO in the bag, the Rockville biotech now turns to a bigger gamble: seeing two drugs through Food and Drug Administration approval and onto the commercial market.